A randomized controlled clinical trial tested an augmented reality (AR) application in pediatric dental care. Ninety-six children, aged 6–8 years and scheduled for pulpotomy, were randomized into three equal groups: Control (CG), Cartoon (CaG), and AR (ARG), with 32 children allocated to each arm. The study team reported outcomes using behavioral, psychological, and physiological measures taken before and after treatment. Behavioral scoring used the Frankl Behavior Rating Scale (FBRS). Self-reported comfort and anxiety were assessed with the Wong-Baker FACES (WB-FACES) and the Modified Child Dental Anxiety Scale [MCDAS(f)]. Physiological measurements included pulse rate and salivary biomarkers: cortisol, α-amylase, and chromogranin-A (CHGA). Ethics committee approval and patient consent were obtained, and the trial was registered at ClinicalTrials.gov (NCT06530654). The authors noted adherence to CONSORT and CONSORT PRO reporting standards.
Behavioral measures favored the AR intervention. The study team observed higher post-treatment FBRS scores in the ARG compared with both the CG and CaG (p = 0.011 and p = 0.041 respectively), indicating better cooperation in children who used the AR application. Short, clear result: AR improved observed behavior. Self-reported measures were more nuanced. Post-treatment WB-FACES scores were lower in ARG than the CG (p = 0.034), suggesting lower reported pain or greater comfort in the AR group relative to standard care. Baseline MCDAS(f) scores were lower in the ARG, however, and after statistical adjustment the post-treatment MCDAS(f) remained significantly lower in ARG versus CaG (p < 0.001) but not versus CG (p = 0.121). This pattern means reported dental anxiety showed some improvement with AR when compared to cartoon distraction, but not uniformly across all comparators.
The cohort-level picture was therefore mixed. Observationally, children using the AR application cooperated better during pulpotomy. Self-reported anxiety and comfort measures supported AR's benefit in some comparisons but failed to demonstrate consistent superiority against standard care across all anxiety scales.
Physiological data produced inconsistent signals. The investigators measured changes in pulse rate and three salivary stress biomarkers pre- and post-treatment. Pulse rate showed a within-group change only in the ARG (p = 0.001); the authors reported no statistically significant differences between groups for pulse rate. In other words, heart-rate changes occurred among children in the AR arm but did not differ robustly from changes in the other arms.
Salivary biomarkers diverged. Cortisol reduction after treatment was greater in the ARG than in both the CG and CaG (p = 0.030 and p = 0.020), indicating a stronger cortisol response associated with AR. The ARG also showed a greater reduction in α-amylase compared with the CG (p = 0.001). By contrast, CHGA reduction was greater in the CaG than in the ARG (p = 0.005). These opposing directions across biomarkers mean physiological stress responses did not move uniformly in one direction with AR exposure. The data indicated selective biomarker changes rather than a consistent stress-lowering effect across all measured parameters.
Clinically, that matters. Behavioral cooperation improved with AR, and some biomarkers followed that trend, but other markers favored the simple cartoon intervention. The trial did not demonstrate across-the-board superiority of AR for physiological stress reduction.
The protocol and reporting conformed to CONSORT and CONSORT PRO guidance, and the authors confirmed ethics committee approval and informed consent procedures. Trial registration is recorded (ClinicalTrials.gov NCT06530654). The investigators integrated elements described as tell-show-do and positive reinforcement into the AR application; the Abstract states this combination is among the first to be evaluated in pediatric dentistry.
Limitations were explicit in the authors' conclusions. The effects of augmented reality on anxiety and physiological stress markers were inconsistent, and the study did not demonstrate overall superiority of AR compared with control or cartoon distraction. The Abstract does not report longer-term follow-up beyond immediate pre- and post-treatment measures; it also does not specify whether subgroup analyses by sex or baseline anxiety were conducted. The source did not report additional details such as exact AR content parameters, duration of exposure, or the timing of biomarker sampling relative to treatment beyond what is stated in the core methods. Those details were not provided in the Abstract and therefore cannot be inferred here.
Unanswered clinical questions remain. Which components of AR (interactive elements, distraction content, reinforcement mechanics) drive behavioral improvement? Do biomarker changes translate to clinically meaningful anxiety reduction over multiple visits? The trial provides evidence that AR can improve cooperation during a single pulpotomy visit, but further trials with pre-specified subgroup analyses, standardized biomarker timing, and longer-term outcomes will be required to define its role more precisely.